TLTFF
Theralase Technologies Inc.
Mentions (24Hr)
0.00% Today
Reddit Posts
Mentions
Its probably for ruvidar bladder cancer trial. If Rutherrin for herpes and cancer ever passes GLP this will be worth untold amounts now that they are likely about to be legitimized with a large pharma company I think. No more mom and pop shop. Big players will have to take them seriously. I don't expect much tomorrow to be fair. Maybe a jump to 30 or 40 cents for TLTFF. But thats a start. Some think this is going to the $1 range tomorrow but who knows.
Just to post and share some news from TLTFF releases. They mentioned in their corporate news release an investment bank is going to back them through an ADR. Which would bring them to the US market and no longer be OTC. Its very interesting technology and if they do make it to the us market in the next 12 months the value would explode as investment banks be allowed to buy in. And the company can stop raising money through private placements to survive. But at the very least extremely impressive results and interesting technology
Your post with title "Theralase (TLTFF) - Lymphoma news release" has been removed from r/pennystocks because it is too short. Posts must have at least 50 characters to ensure meaningful discussions. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
$TLT or $TLTFF - Theralase Technologies, trying for a FDA BTD Q1 24 approval, operating on fumes cash wise. will probably go to 0
Awesome News today! Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine Toronto, Ontario – February 7, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 (“PDC”) and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (“COVID-19”) vaccine. In August 2020, Theralase® reported that it had executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) medical microbiology department to commence research and development of a Canadian-made vaccine, utilizing Theralase®’s patented and proprietary PDC, TLD-1433. In November 2020, Theralase® reported that, UM was able to demonstrate that TLD-1433 was effective in the rapid destruction of various viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations. All these enveloped viruses are similar in structure to SARS-CoV-2 virus (BSL-3), which is responsible for COVID-19. These initial results strongly suggested that Theralase®’s PDC technology may be used to develop an inactivated virus vaccine2 that may be effective against COVID-19 and hence warranted further preclinical evaluation. Further research by UM also identified that the spike protein responsible for the transmission of a coronavirus into a host cell, remained intact after light-activated TLD-1433 inactivation, suggesting that the vaccine developed by this technology could potentially stimulate a protective antibody immune response in a mammalian host. In April 2021, Theralase® reported that it had executed a Collaborative Research Agreement (“CRA”) with the Public Health Agency of Canada’s (“PHAC”) National Microbiology Laboratory to further expand upon the research and development achieved at UM, by researching and developing a Canadian-based COVID-19 vaccine. Under the terms of the agreement, Theralase® and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralase®’s light-activated PDC, TLD-1433. Theralase® is pleased to be able to report today that PHAC has demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study. Further research is required to confirm these findings. These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus. Darwyn Kobasa, Ph.D., Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC, stated "My team’s initial results indicate that, when activated by light, TLD-1433 is very effective in inactivating the COVID-19 virus at low concentrations, thus demonstrating proof-of-concept in the development of a Canadian-made COVID-19 vaccine.” Kevin Coombs, Ph.D., Professor, Department of Medical Microbiology at UM, stated, “The work conducted at my lab and the work conducted by PHAC’s National Microbiology Laboratory, has demonstrated that a large range of enveloped viruses can be successfully inactivated by light-activated TLD-1433 at low concentrations. I am delighted that Theralase®’s and my initial preclinical research has proven to be effective in COVID-19. Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “The latest preliminary results by Dr. Kobasa and Dr. Coombs, demonstrates that the Theralase® vaccine may potentially be effective as a Canadian-made wholly-inactivated vaccine to prevent individuals from contracting COVID-19 in the future and warrants further research to confirm the findings. The research also demonstrates that the Theralase® platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses. This would allow the Company to tailor the vaccine to be potentially effective against contracting various viruses (existing and/or new) and their associated variants. Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase® COVID-19 vaccine, subject to the required regulatory approval.” 1 PDCs are Light sensitive compounds that when activated by light at a particular wavelength can produce reactive oxygen species that can cause inactivation of cells or viruses through oxidative stress. 2 The Company does not claim or profess that they have the ability to treat, cure or prevent the contraction of the COVID-19 coronavirus. About TLD-1433 TLD-1433 is a patented PDC with over 10 years of published peer reviewed preclinical research and is currently under investigation in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study for Bacillus Calmette-Guérin (“BCG”)-Unresponsive patients at 5 Canadian Clinical Study Sites (“CSS”) and 7 US-based CSS. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses. Additional information is available at www.theralase.com and www.sedar.com
TLTFF is my penny play. They have cure for bladder cancer using photodynamic compounds and lasers. Should also be applicable for others...